RVNC - Revance Therapeutics, Inc.
IEX Last Trade
3.08
-2.900 -94.156%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$5.98
-2.90
-48.49%
Fundamental analysis
17%
Profitability
0%
Dept financing
11%
Liquidity
75%
Performance
20%
Performance
5 Days
-0.32%
1 Month
-18.95%
3 Months
-41.89%
6 Months
31.06%
1 Year
-64.06%
2 Year
-84.29%
Key data
Stock price
$3.08
DAY RANGE
$3.07 - $5.98
52 WEEK RANGE
$2.41 - $9.74
52 WEEK CHANGE
-$65.66
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Mark J. Foley
Region: US
Website: revance.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: revance.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Revance Therapeutics, Inc. engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia.
Recent news